YARDLEY, Pa., August 24, 2026
Savara Inc. will present new and previously reported Phase 3 IMPALA-2 clinical trial data for molgramostim inhalation solution in patients with autoimmune pulmonary alveolar proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain, from September 5–9. The company has secured one oral presentation and two poster presentations, focusing on long-term efficacy and safety, exercise capacity and disease biomarkers. The presentations will provide additional clinical evidence supporting molgramostim as a potential treatment for a rare respiratory disease with no approved pharmacologic treatment.
Savara to Present Long-Term IMPALA-2 Findings
The centerpiece of Savara’s ERS program will be an oral presentation covering long-term efficacy and safety results from the open-label period of the IMPALA-2 Phase 3 trial. The presentation is scheduled for September 6, 2026, during the session on clinical and scientific advances in rare lung diseases. According to Savara, the data include outcomes through the first 48 weeks of open-label treatment, with the company highlighting continued improvements in lung function, exercise capacity and quality of life. The high retention rate and durability of treatment effects are also expected to be important components of the presentation as Savara advances molgramostim toward its potential role in long-term management of aPAP.
Exercise Capacity and Biomarker Data Add Clinical Depth
Two additional IMPALA-2 presentations will examine clinically relevant measures that extend beyond conventional lung-function assessments. One poster will focus on the ability of molgramostim to improve exercise capacity, walking distance and exercise duration, providing evidence on functional outcomes that can directly affect daily activities for patients with aPAP. A second poster will examine biomarker levels associated with aPAP disease severity, potentially providing insight into how treatment affects the underlying disease biology. Savara said reductions in biomarkers of disease severity, together with improvements in clinical measures, support the potential of molgramostim to address important aspects of the disease rather than focusing solely on symptoms
Advertisement
Molgramostim Targets the Underlying aPAP Mechanism
Autoimmune pulmonary alveolar proteinosis is a rare lung disease in which surfactant accumulates abnormally inside the alveoli, impairing normal gas exchange. The disease is driven by antibodies that neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), preventing alveolar macrophages from effectively clearing excess surfactant. Molgramostim, a recombinant human GM-CSF, is designed to restore this biological pathway and support surfactant clearance. Savara is developing the therapy as an inhaled treatment using a proprietary investigational eFlow nebulizer system. At ERS 2026, the company will also host an industry evening mini-symposium titled “Autoimmune Pulmonary Alveolar Proteinosis: From Disease Mechanisms to Clinical Management,” bringing together experts to discuss disease biology and clinical management. The presentations collectively reinforce Savara’s focus on developing a potential long-term treatment option for patients affected by this rare respiratory disorder.
Source:Savara press relese
